An effective drug against COVID-19: reality or dream?

References

• Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H, Bickerton E, Britton P (eds) Coronaviruses. Methods in Molecular Biology, vol 1282. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2438-7_1
   Google Scholar
• Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 2005;24(11):S223–S7.
   PubMedGoogle Scholar
• Peiris J. 2017. Coronaviruses, p 1243-1265. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch52
   Google Scholar
• de Groot R, Baker S, Baric R, et al. Family Coronaviridae. Virus taxonomy: classification and nomenclature of viruses: ninth report of the International Committee on Taxonomy of Viruses; 2012; Amsterdam, The Netherlands: Elsevier/Academic Press. p 806–820
   Google Scholar
• Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966.
   PubMed Web of Science ®Google Scholar
• Peiris J, Lai S, Poon L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319–1325.
   PubMed Web of Science ®Google Scholar
• Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Nat Acad Sci. 2005;102(39):14040–14045.
   PubMed Web of Science ®Google Scholar
• Zaki AM, Van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• Organization WH. Middle East respiratory syndrome coronavirus (MERS-CoV): summary of current situation, literature update and risk assessment. World Health Organization, 2015.
   Google Scholar
• Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019nCoV): a systematic review. Journal of clinical medicine. 2020;9(3):623
   Google Scholar
• Millán-Oñate J, Rodriguez-Morales AJ, Camacho-Moreno G, et al. A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19). Infectio. 2020;24(3):187-192.
   Google Scholar
• McBride R, Van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991–3018.
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116.
   PubMed Web of Science ®Google Scholar
• Walls AC, Tortorici MA, Frenz B, et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol. 2016;23(10):899.
   PubMed Web of Science ®Google Scholar
• Walls AC, Xiong X, Park Y-J, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell. 2019;176(5): 1026–39. e15.
   PubMed Web of Science ®Google Scholar
• Xiong X, Tortorici MA, Snijder J, et al. Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections. J Virol. 2018;92(4):e01628–17.
   PubMed Web of Science ®Google Scholar
• Yang X-L, Hu B, Wang B, et al. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. J Virol. 2016;90(6):3253–3256.
   Web of Science ®Google Scholar
• Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Nat Acad Sci. 2009;106(14):5871–5876.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, van der Zee R, de Haan CA, et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811.
   PubMed Web of Science ®Google Scholar
• Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014;10(11):e1004709.
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN, Cottrell CA, Wang N, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118–121.
   PubMed Web of Science ®Google Scholar
• Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Nat Acad Sci. 2017;114(35):E7348–E57.
   PubMed Web of Science ®Google Scholar
• Hulswit RJ, Lang Y, Bakkers MJ, et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc Nat Acad Sci. 2019;116(7):2681–2690.
   PubMed Web of Science ®Google Scholar
• Park J-E, Li K, Barlan A, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Nat Acad Sci. 2016;113(43):12262–12267.
   PubMed Web of Science ®Google Scholar
• Li W, Hulswit RJ, Widjaja I, et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Nat Acad Sci. 2017;114(40):E8508–E17.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. bioRxiv. 2020;181(2):281–292.e6.
   Google Scholar
• Xiu S, Dick A, Ju H, et al. Inhibitors of SARS-CoV-2 entry: current and future opportunities. J Med Chem. 2020;63:12256–12274.
   PubMed Web of Science ®Google Scholar
• Gil C, Ginex T, Maestro I, et al. COVID-19: drug targets and potential treatments. J Med Chem. 2020;63:12359–12386.
   Web of Science ®Google Scholar
• Peiris JS, Yuen KY, Osterhaus AD, et al. The severe acute respiratory syndrome. N Engl J Med. 2003;349(25):2431–2441.
   PubMed Web of Science ®Google Scholar
• Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7.
   Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4): 420–422.
   PubMed Web of Science ®Google Scholar
• Calisher C, Carroll D, Colwell R, et al. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet. 2020;395:e42-e43.
   PubMed Web of Science ®Google Scholar
• Carlos WG, Dela Cruz CS, Cao B, et al. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. 2020;201:P7-P8. (ja).
   PubMed Web of Science ®Google Scholar
• Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–761.
   PubMed Web of Science ®Google Scholar
• Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–1994.
   PubMed Web of Science ®Google Scholar
• Phan LT, Nguyen TV, Luong QC, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020;382(9):872–874.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Roberto Giacobbe D. The Novel Chinese Coronavirus (2019‐nCoV) Infections: challenges for fighting the storm. Eur J Clin Invest. 2020;50:e13209.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020;31:929042v1.
   Google Scholar
• Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395:809–815.
   Web of Science ®Google Scholar
• Siegel D, Hui HC, Doerffler E, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo [2, 1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Washington, D.C.: ACS Publications; 2017.
   Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1): 1–14.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Madsen LW. Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med. 2020;338:1813-1826.
   Web of Science ®Google Scholar
• Gharibnaseri Z, Olyaeemanesh A. Safety and efficacy of remdesivir in the treatment of Covid-19: a rapid review of available evidence. Health Technol Assess Action. 2020;4(1):32-39.
   Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. BioRxiv. 2020;15:043166.
   Google Scholar
• Burwick RM, Yawetz S, Stephenson KE, et al. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clinl Infect Dis. 2020;8:1-9.
   PubMedGoogle Scholar
• Remdesivir (VEKLURY) [package insert]. Food and Drug Administration. 2020 Oct 25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf
   Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B. 2017;93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85–94.
   PubMed Web of Science ®Google Scholar
• Warren T, MacLennan S, Mathis A, et al., editors. Efficacy of galidesivir against ebola virus disease in rhesus monkeys. Open forum infectious diseases. Walton Street: Oxford University Press; 2017.
   Google Scholar
• Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Ismail AM. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. SAR QSAR Environ Res. 2018;29(5):409–418.
   PubMed Web of Science ®Google Scholar
• Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856.
   PubMed Web of Science ®Google Scholar
• Yang SN, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760.
   PubMed Web of Science ®Google Scholar
• Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals Antiviral research. 2012;95(3):202–206.
   Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Chu C, Cheng V, Hung I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913.
   PubMed Web of Science ®Google Scholar
• Que T, Wong V, Yuen K. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399–406.
   PubMedGoogle Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
   Web of Science ®Google Scholar
• Deutsch M, Papatheodoridis GV. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr Opin Invest Drugs. 2010;11(8):951–963. (London, England: 2000)
   PubMedGoogle Scholar
• Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234.
   PubMedGoogle Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913.e7.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;3(11):722–727.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.
   PubMed Web of Science ®Google Scholar
• Molina JM, Delaugerre C, Goff JL, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:30085–30088.
   Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382:2411–2418.
   PubMed Web of Science ®Google Scholar
• Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study. medRxiv. 2020;15(8):e0237693.
   Google Scholar
• Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;31180-6.
   Web of Science ®Google Scholar
• Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020;23:16. Preprint posted April
   Google Scholar
• Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Nat Acad Sci. 2017;114(2):206–214.
   PubMed Web of Science ®Google Scholar
• Uno Y. Camostat mesilate therapy for COVID-19. Intern Emerg Med. 2020;15:1–2.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.
   Web of Science ®Google Scholar
• Herold T, Jurinovic V, Arnreich C, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv. 2020;146:128-136.e4.
   Google Scholar
• Rose-John S, Waetzig GH, Scheller J, et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007;11(5):613–624.
   PubMed Web of Science ®Google Scholar
• Razanamahery J, Humbert S, Gil H, et al. Tropheryma Whipplei infection mimicking giant cell arteritis flare in a patient treated with interleukin-6 receptor blocker tocilizumab. Clin Exp Rheumatol. 2020;124:245-246.
   Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020. DOI:10.1001/jama.2020.6019
   PubMed Web of Science ®Google Scholar
• Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570.
   PubMed Web of Science ®Google Scholar
• Dastan F, Tabarsi P, Marjani M, et al. Thalidomide against Coronavirus Disease 2019 (COVID-19): a medicine with a thousand faces. Iran J Pharm Res. 2020;19(1):1–2.
   Web of Science ®Google Scholar
• Vargesson N. Thalidomide‐induced teratogenesis: history and mechanisms. Birth Defects Res Part C: Embryo Today: Rev. 2015;105(2):140–156.
   PubMedGoogle Scholar
• Lee N, Chan KA, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–309.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV). Expert Rev Anti Infect Ther. 2017;15(3):269–275.
   PubMed Web of Science ®Google Scholar
• Toots M, Yoon -J-J, Hart M, et al. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2019;218:16-28.
   PubMed Web of Science ®Google Scholar
• Dhody K, Pourhassan N, Kazempour K, et al. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials. 2018;19(3):85–93.
   PubMed Web of Science ®Google Scholar
• First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated Vancouver, Washington. 2020 Apr 6. cited 2020 Apr 8. cytodyn.com/newsroom/press-releases/detail/409/first-two-patients-enrolled-in-randomized-phase-2-covid-19
   Google Scholar
• Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400.
   PubMed Web of Science ®Google Scholar
• Soo Y, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676–678.
   PubMed Web of Science ®Google Scholar
• Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4(1):1–8.
   PubMedGoogle Scholar
• Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinl Infect Dis. 2011;52(4):447–456.
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90.
   PubMed Web of Science ®Google Scholar
• Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323:1582.
   Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. editors. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open forum infectious diseases. Walton Street: Oxford University Press US; 2020.
   Google Scholar
• Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256.
   Google Scholar
• Wang C, Li W, Drabek D. A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv. 2020;12. Preprint posted online March
   Google Scholar
• Choudhry N, Zhao X, Xu D, et al. Chinese therapeutic strategy for fighting COVID-19 and potential small-molecule inhibitors against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). J Med Chem. 2020.
   PubMed Web of Science ®Google Scholar